03 Profile
Hansard to 4 November 2026 · 31,174 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Sector leader · Rare diseases
Oskar Ahlberg
vice-president of Rare Disease Sweden
press citation on 1 topic since 2 Jun 2026 · last quoted 2 Jun 2026
02 Quoted on · 1 of 29 topics
Oskar Ahlberg: key facts
- Kind of voice
- Sector leader
- Role
- vice-president of Rare Disease Sweden
- Quoted on
- Rare diseases
- Tracked press citations
- 1
- Most recently quoted
- 2 Jun 2026
04 The signal · where Oskar Ahlberg sits on rare diseases
Ranked 25= of 231 voices quoted in the press on rare diseases, level with 206 others on 1 citation.
Ranked on press citations on this topic only, not across all topics. Joint positions share a rank.
- 1=Vinay PrasadAcademicProfessor of Epidemiology and Biostatistics and Medicine; hematologist-oncologist, University of California, San Francisco (UCSF)4
- 1=David WeitzAcademicMallinckrodt Professor of Physics and of Applied Physics; Professor of Systems Biology, Harvard University (John A. Paulson School of Engineering and Applied Sciences)4
- 1=Tuomas KnowlesAcademic1920 Professor of Physical Chemistry, University of Cambridge4
- 25=Anna AlassaadSector leaderchief strategist at the TLV, the Swedish Dental and Pharmaceutical Benefits Agency1
- 25=Katarina AntonovSector leaderhead of analysis at LIF, the Swedish Association of Research-Based Pharmaceutical Companies1
- 25=Oskar AhlbergSector leadervice-president of Rare Disease Sweden1
- 25=Mark JanssenSector leaderchairperson of the Dutch Healthcare Institute1
- 25=Dr Brian Hon-yin ChungAcademicClinical Associate Professor at The University of Hong Kong and Chief Executive Officer of the Hong Kong Genome Institute1
Showing the leaders and the ranks around 25=, of 231 voices · See every voice on the topic →
05 On the record · press
What Oskar Ahlberg has said
- euractiv.com1
Where Oskar Ahlberg has been quoted
- 01Swedish rare disease patients endure longer wait for new medicineseuractiv.com · 2 Jun 2026
Verbatim
“Companies may choose not to market an orphan drug in Sweden if, for example, the patient population is very small. However, recent data from the industry suggests that many still apply for reimbursement.”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
Chief executives, directors and spokespeople of trade bodies, representative associations and charities speaking for the sector. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.